1. Critically ill COVID-19 patients who have been tested positive by RT-PCR for SARS-CoV-2 on the nasopharyngeal or throat swabs. <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- SpO2 â?¤90% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

1. Critically ill COVID-19 patients who have been tested positive by RT-PCR for SARS-CoV-2 on the nasopharyngeal or throat swabs. <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- SpO2 â?¤90% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

1. Critically ill COVID-19 patients who have been tested positive by RT-PCR for SARS-CoV-2 on the nasopharyngeal or throat swabs. <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- SpO2 â?¤90% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

1. Critically ill COVID-19 patients who have been tested positive by RT-PCR for SARS-CoV-2 on the nasopharyngeal or throat swabs. <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- SpO2 â?¤90% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

1. Critically ill patients infected with COVID-19 (clinical/confirmed) <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or <br/ >- SpO2 â?¤94% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.

1. Critically ill patients infected with COVID-19 (clinical/confirmed) <br/ >2. Patient aged 18 years or more of either gender <br/ >3. Illness of any duration with respiratory rate â?¥25 breaths/minute, and at least one of the following: <br/ >- Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or <br/ >- SpO2 â?¤94% on room air, or <br/ >- Requiring mechanical ventilation and/or supplemental oxygen <br/ >4. Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. <br/ >5. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure.